PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia
The DOI matches its Crossref record; 57 of the 60 references it cites were found in a registry or an index.
Abstract
Targeting B-cell receptor signaling using the PI3Kδ inhibitor idelalisib is a highly effective treatment option for relapsed/refractory chronic lymphocytic leukemia (CLL) patients. In addition to its direct impact on tumor cells, PI3Kδ inhibition can modulate the activity of regulatory T-cells (Tregs) resulting in enhanced anti-tumoral immune functions which may contribute to the success of PI3Kδ inhibitors in cancer therapy. The role of Tregs in CLL and their modulation by PI3Kδ inhibitors was so far poorly understood. Using the Eµ-TCL1 adoptive transfer model of CLL, we show that disease development induces the accumulation of activated and highly immunosuppressive Tregs. Depletion of CD25+ Tregs using anti-CD25 antibodies resulted in enhanced CD8+ T-cell activation, effector differentiation, and functional capacity. We further show that pharmacological inhibition of PI3Kδ effectively controlled disease and significantly decreased both CD25+ and CD25- Treg numbers, proliferation and activation status in CLL-bearing mice. Nonetheless, this PI3Kδ-mediated decrease in Tregs did not translate into better CD8+ T-cell function, as PI3Kδ inhibition concomitantly abrogated T-cell receptor signaling in CD8+ T-cells leading to decreased activation, effector cell differentiation and proliferation. Collectively, these data highlight the strong immunomodulatory effects of PI3Kδ inhibitors in CLL and are of relevance for a rational design of idelalisib-based combination therapies in CLL.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“mice bearing an inactivating mutation in Pik3cd exhibit superior resistance to chronic lymphocytic leukemia (CLL) in the context of impaired TREG cell expansion (Dong et al., 2019; Hanna et al., 2019)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Hanna et al., 2019
Citations
Cites
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Regulatory T cells: mechanisms of differentiation and function
Josefowicz, S. Z., Lu, L.-F., & Rudensky, A. Y. (2012) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141623 · Cited by 2,866
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grünhagen, U., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61381-5 · Cited by 1,888
Self-citationIdelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,710
Self-citationIbrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,639
PI3Kγ is a molecular switch that controls immune suppression
Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,173
Moran, A. E., Holzapfel, K. L., Xing, Y., Cunningham, N. R., Maltzman, J. S., Punt, J., & Hogquist, K. A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110308 · Cited by 1,034
Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice
Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S. E., Salpekar, A., Waterfield, M. D., et al. (2002) · Science · doi:10.1126/science.1073560 · Cited by 946
Herishanu, Y., Pérez-Galán, P., Liu, D., Biancotto, A., Pittaluga, S., Vire, B., Gibellini, F., Njuguna, N., Lee, E., Stennett, L., et al. (2011) · Blood · doi:10.1182/blood-2010-05-284984 · Cited by 815
PI3K in lymphocyte development, differentiation and activation
Okkenhaug, K., & Vanhaesebroeck, B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1056 · Cited by 810
Ramsay, A. G., Johnson, A. J., Lee, A. M., Gorgün, G., Le Dieu, R., Blum, W., Byrd, J. C., & Gribben, J. G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35017 · Cited by 600
Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression
Bichi, R., Shinton, S. A., Martin, E. S., Koval, A., Calin, G. A., Cesari, R., Russo, G., Hardy, R. R., & Croce, C. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.102181599 · Cited by 582
Regulatory circuits of T cell function in cancer
Speiser, D. E., Ho, P.-C., & Verdeil, G. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.80 · Cited by 566
From pathogenesis to treatment of chronic lymphocytic leukaemia
Zenz, T., Mertens, D., Küppers, R., Döhner, H., & Stilgenbauer, S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2764 · Cited by 553
Self-citationHoellenriegel, J., Meadows, S. A., Sivina, M., Wierda, W. G., Kantarjian, H., Keating, M. J., Giese, N., O'Brien, S., Yu, A., Miller, L. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-352492 · Cited by 549
Herman, S. E. M., Gordon, A. L., Wagner, A. J., Heerema, N. A., Zhao, W., Flynn, J. M., Jones, J., Andritsos, L., Puri, K. D., Lannutti, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271171 · Cited by 543
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Ali, K., Soond, D. R., Piñeiro, R., Hagemann, T., Pearce, W., Lim, E. L., Bouabe, H., Scudamore, C. L., Hancox, T., Maecker, H., et al. (2014) · Nature · doi:10.1038/nature13444 · Cited by 529
Riches, J. C., Davies, J. K., McClanahan, F., Fatah, R., Iqbal, S., Agrawal, S., Ramsay, A. G., & Gribben, J. G. (2013) · Blood · doi:10.1182/blood-2012-09-457531 · Cited by 529
Beyer, M., Kochanek, M., Darabi, K., Popov, A., Jensen, M., Endl, E., Knolle, P. A., Thomas, R. K., von Bergwelt-Baildon, M., Debey, S., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0642 · Cited by 492
Fischer, K., Cramer, P., Busch, R., Böttcher, S., Bahlo, J., Schubert, J., Pflüger, K. H., Schott, S., Goede, V., Isfort, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2688 · Cited by 433
Self-citationPerturbation of the normal immune system in patients with CLL
Forconi, F., & Moss, P. (2015) · Blood · doi:10.1182/blood-2015-03-567388 · Cited by 385
PI3Kδ and primary immunodeficiencies
Lucas, C. L., Chandra, A., Nejentsev, S., Condliffe, A. M., & Okkenhaug, K. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.93 · Cited by 342
Burger, J. A., Keating, M. J., Wierda, W. G., Hartmann, E., Hoellenriegel, J., Rosin, N. Y., de Weerdt, I., Jeyakumar, G., Ferrajoli, A., Cardenas-Turanzas, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70335-3 · Cited by 332
B cell receptor signaling in chronic lymphocytic leukemia
Burger, J. A., & Chiorazzi, N. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.07.002 · Cited by 327
Patton, D. T., Garden, O. A., Pearce, W. P., Clough, L. E., Monk, C. R., Leung, E., Rowan, W. C., Sancho, S., Walker, L. S. K., Vanhaesebroeck, B., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.6598 · Cited by 303
Lampson, B. L., Kasar, S. N., Matos, T. R., Morgan, E. A., Rassenti, L., Davids, M. S., Fisher, D. C., Freedman, A. S., Jacobson, C. A., Armand, P., et al. (2016) · Blood · doi:10.1182/blood-2016-03-707133 · Cited by 285
Flinn, I. W., O’Brien, S., Kahl, B., Patel, M., Oki, Y., Foss, F. F., Porcu, P., Jones, J., Burger, J. A., Jain, N., et al. (2018) · Blood · doi:10.1182/blood-2017-05-786566 · Cited by 252
Jitschin, R., Braun, M., Büttner, M., Dettmer-Wilde, K., Bricks, J., Berger, J., Eckart, M. J., Krause, S. W., Oefner, P. J., Le Blanc, K., et al. (2014) · Blood · doi:10.1182/blood-2013-12-546416 · Cited by 251
Zelenetz, A. D., Barrientos, J. C., Brown, J. R., Coiffier, B., Delgado, J., Egyed, M., Ghia, P., Illés, Á., Jurczak, W., Marlton, P., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30671-4 · Cited by 250
Self-citationZelenay, S., Lopes-Carvalho, T., Caramalho, I., Moraes-Fontes, M. F., Rebelo, M., & Demengeot, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408679102 · Cited by 232
Therapeutic opportunities for manipulating TReg cells in autoimmunity and cancer
von Boehmer, H., & Daniel, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3683 · Cited by 220
Burris, H. A., Flinn, I. W., Patel, M. R., Fenske, T. S., Deng, C., Brander, D. M., Gutierrez, M., Essell, J. H., Kuhn, J. G., Miskin, H. P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30082-2 · Cited by 205
McClanahan, F., Hanna, B., Miller, S., Clear, A. J., Lichter, P., Gribben, J. G., & Seiffert, M. (2015) · Blood · doi:10.1182/blood-2015-01-622936 · Cited by 188
Self-citationDiLillo, D. J., Weinberg, J. B., Yoshizaki, A., Horikawa, M., Bryant, J. M., Iwata, Y., Matsushita, T., Matta, K. M., Chen, Y., Venturi, G. M., et al. (2013) · Leukemia · doi:10.1038/leu.2012.165 · Cited by 175
Idelalisib in the management of lymphoma
Cheah, C. Y., & Fowler, N. H. (2016) · Blood · doi:10.1182/blood-2016-02-702761 · Cited by 162
D’Arena, G., Laurenti, L., Minervini, M. M., Deaglio, S., Bonello, L., De Martino, L., De Padua, L., Savino, L., Tarnani, M., De Feo, V., et al. (2011) · Leukemia Research · doi:10.1016/j.leukres.2010.08.010 · Cited by 161
Wierz, M., Pierson, S., Guyonnet, L., Viry, E., Lequeux, A., Oudin, A., Niclou, S. P., Ollert, M. W., Berchem, G., Janji, B., et al. (2018) · Blood · doi:10.1182/blood-2017-06-792267 · Cited by 146
Hanna, B. S., McClanahan, F., Yazdanparast, H., Zaborsky, N., Kalter, V., Rößner, P. M., Benner, A., Dürr, C., Egle, A., Gribben, J. G., et al. (2015) · Leukemia · doi:10.1038/leu.2015.305 · Cited by 144
Self-citationMoreira, J., Rabe, K. G., Cerhan, J. R., Kay, N. E., Wilson, J. W., Call, T. G., Leis, J. F., Jelinek, D. F., Schwager, S. M., Bowen, D. A., et al. (2012) · Leukemia · doi:10.1038/leu.2012.187 · Cited by 128
McClanahan, F., Riches, J. C., Miller, S., Day, W. P., Kotsiou, E., Neuberg, D., Croce, C. M., Capasso, M., & Gribben, J. G. (2015) · Blood · doi:10.1182/blood-2015-02-626754 · Cited by 114
The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells
Saulep-Easton, D., Vincent, F. B., Quah, P. S., Wei, A., Ting, S. B., Croce, C. M., Tam, C., & Mackay, F. (2016) · Leukemia · doi:10.1038/leu.2015.174 · Cited by 101
Phosphoinositide 3–kinase γ participates in T cell receptor–induced T cell activation
Alcázar, I., Marqués, M., Kumar, A., Hirsch, E., Wymann, M. P., Carrera, A. C., & Barber, D. F. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070366 · Cited by 88
Hanna, B. S., Roessner, P. M., Yazdanparast, H., Colomer, D., Campo, E., Kugler, S. J., Yosifov, D. Y., Stilgenbauer, S., Schmidt, M., Gabriel, R., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0250-6 · Cited by 81
Self-citationRegulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia
Weiß, L., Melchardt, T., Egle, A., Grabmer, C., Greil, R., & Tinhofer, I. (2010) · Cancer · doi:10.1002/cncr.25752 · Cited by 69
Yahiaoui, A., Meadows, S. A., Sorensen, R. A., Cui, Z.-H., Keegan, K. S., Brockett, R., Chen, G., Quéva, C., Li, L., & Tannheimer, S. L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171221 · Cited by 54
Leukemic challenge unmasks a requirement for PI3Kδ in NK cell–mediated tumor surveillance
Zebedin, E., Simma, O., Schuster, C., Putz, E. M., Fajmann, S., Warsch, W., Eckelhart, E., Stoiber, D., Weisz, E., Schmid, J. A., et al. (2008) · Blood · doi:10.1182/blood-2008-02-139105 · Cited by 44
PI3Kδ Regulates the Magnitude of CD8+ T Cell Responses after Challenge with Listeria monocytogenes
Pearce, V. Q., Bouabe, H., MacQueen, A. R., Carbonaro, V., & Okkenhaug, K. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501227 · Cited by 36
Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander?
D'Arena, G. F., Simeon, V., D’Auria, F., Statuto, T., Sanzo, P. D., Martino, L. D., Marandino, A., Sangiorgio, M., Musto, P., & Feo, V. D. (2013) · Europe PMC (PubMed Central) · Cited by 35
PI3Kδ Is Essential for Tumor Clearance Mediated by Cytotoxic T Lymphocytes
Putz, E. M., Prchal-Murphy, M., Simma, O. A., Forster, F., Koenig, X., Stockinger, H., Piekorz, R. P., Freissmuth, M., Müller, M., Sexl, V., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040852 · Cited by 35
PI3Kgamma (PI3Kγ) is essential for efficient induction of CXCR3 on activated T cells
Barbi, J. J., Cummings, H., Lu, B., Oghumu, S., Rückle, T., Rommel, C., Lafuse, W. P., Whitacre, C. C., & Satoskar, A. R. (2008) · Blood · doi:10.1182/blood-2008-02-135715 · Cited by 33
Gracias, D. T., Boesteanu, A. C., Fraietta, J. A., Hope, J. L., Carey, A. J., Mueller, Y. M., Kawalekar, O. U., Fike, A. J., June, C. H., & Katsikis, P. D. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501890 · Cited by 30
Phosphoinositide 3‐kinase gamma; participates in T cell receptor‐induced T cell activation.
Alcázar, I., Marqués, M., Kumar, A., Hirsch, E., Wymann, M. P., Carrera, A. C., & Barber, D. F. (2008) · The FASEB Journal · doi:10.1096/fasebj.22.1_supplement.1064.12 · Cited by 29
The dilemma of anticancer therapy: tumor-specific versus immune effects
Zitvogel, L., & Kroemer, G. (2008) · Blood · doi:10.1182/blood-2008-09-176693 · Cited by 11
Inactivation of PI(3)K p110 delta breaks regulatory T-cell-mediated immune tolerance to cancer
Ali, K., Soond, D., Pineiro, R., Hagemann, T., Pearce, W. P., Lim, E., Bouabe, H., Scudamore, C., Hancox, T. C., Maecker, H. L., et al. (2014) · UCL Discovery (University College London) · Cited by 9
Weiß, L., Melchardt, T., Grabmer, C., Egle, A., Tinhofer, I., & Greil, R. (2009) · Blood · doi:10.1182/blood.v114.22.1238.1238 · Cited by 5
Cited by
Yan, Y., Huang, L., Liu, Y., Yi, M., Chu, Q., Jiao, D., & Wu, K. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01322-3 · Cited by 212
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?
Roessner, P. M., & Seiffert, M. (2020) · Leukemia · doi:10.1038/s41375-020-0873-2 · Cited by 144
Self-citationde Weerdt, I., Hofland, T., de Boer, R., Dobber, J. A., Dubois, J., van Nieuwenhuize, D., Mobasher, M., de Boer, F., Hoogendoorn, M., Velders, G. A., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000360 · Cited by 110
Cellular and molecular mechanisms breaking immune tolerance in inborn errors of immunity
Sogkas, G., Atschekzei, F., Adriawan, I. R., Dubrowinskaja, N., Witte, T., & Schmidt, R. E. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00626-z · Cited by 102
Metadata
- Authors
- Hanna, B. S., Roessner, P. M., Scheffold, A., Jebaraj, B. M. C., Demerdash, Y., Öztürk, S., Lichter, P., Stilgenbauer, S., & Seiffert, M.
- Affiliations
- German Cancer Research Center (DE)
- University Hospital Ulm (DE)
- Corresponding author
- Hanna, Bola S.
- Seiffert, Martina
- ORCID
- Venue
- Leukemia
- Published
- 2018-12-20
- Volume
- 33
- Issue
- 6
- Pages
- 1427-1438
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2904653639
- Cited by
- 55
- References
- 60
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 10 · 2022: 5 · 2021: 14 · 2020: 16 · 2019: 5
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (SFB1074 project B1)
- Bundesministerium für Bildung und Forschung (Precise, FIRE-CLL, Fire-CLL)
- José Carreras Leukämie-Stiftung (R14/23)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- PI3Kδ inhibition, idelalisib, chronic lymphocytic leukemia, regulatory T cells, CD8+ T cell activation, effector T cell differentiation, T cell receptor signaling, immunomodulation, B cell receptor signaling, combination therapy
- MeSH terms
- Animals, Antineoplastic Agents, Cell Differentiation, Female, Humans, Lymphocyte Activation, Mice, Inbred C57BL, Purines, Tumor Cells, Cultured, Signal Transduction, Leukemia, Lymphocytic, Chronic, B-Cell, CD8-Positive T-Lymphocytes, T-Lymphocytes, Regulatory, Mice, Quinazolinones, Class I Phosphatidylinositol 3-Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.